Top 5 Papers
#1
Source: AACR 2026 / Memorial Sloan Kettering | Authors: Michael Foote, MD et al. (MSK) | Published: April 19, 2026 (AACR 2026)
Score: 10/20 — Base AACR oral presentation (7) + Phase II (+2) + biomarker-guided/precision (+1)
Presented at AACR 2026, this prospective single-arm MSK trial enrolled 10 patients with locally advanced HER2-positive, RAS wild-type, pMMR rectal adenocarcinoma (70% node-positive). Treatment consisted of 6 weeks of trastuzumab + tucatinib followed by 15 weeks of trastuzumab + tucatinib + FOLFOX/CAPOX. Six of eight evaluable patients responded (75% ORR), including four clinical complete responses (50% cCR). Patients achieving cCR transitioned to active surveillance without surgery or radiation. This precision neoadjuvant approach opens a potential watch-and-wait pathway for HER2-amplified rectal cancer, a particularly aggressive subtype.
Post angle: HER2+ rectal cancer meets precision neoadjuvant therapy. 75% ORR, 50% complete responses — and the possibility of avoiding surgery. Organ preservation through molecular targeting is the future. #CRC #RectalCancer #HER2 #AACR2026 #OrganPreservation
#2
Source: FDA / GlobeNewswire | Authors: BridgeBio Oncology Therapeutics (BBOT) | Published: April 20, 2026
Score: 9/20 — Base FDA regulatory action (8) + biomarker-guided/precision (+1)
The FDA granted Fast Track designation to BBO-11818 for adult patients with advanced KRAS-mutant PDAC. BBO-11818 is a first-in-class oral non-covalent small molecule targeting both active (ON) and inactive (OFF) KRAS states, providing pan-KRAS inhibition across G12D, G12V, and other mutations — not limited to G12C. Per ClinicalTrials.gov (NCT06917079), the Phase 1a/1b KONQUER-101 trial is enrolling 387 patients across PDAC, CRC, and NSCLC with combination arms including pembrolizumab, cetuximab, FOLFOX, and NALIRIFOX. Monotherapy has demonstrated confirmed partial responses in PDAC. Updated data expected H2 2026.
Post angle: Pan-KRAS is the holy grail for PDAC. BBO-11818 hits KRAS in both ON and OFF states — covering G12D, G12V, and beyond. 387 patients enrolling with combo arms. Fast Track = FDA urgency. #PDAC #KRAS #PancreaticCancer #FDA #PrecisionMedicine
#3
Source: Pfizer / BusinessWire | Authors: Pfizer Inc. | Published: April 21, 2026
Score: 9/20 — Base Press Release Phase 3 (6) + Phase III RCT (+3)
Pfizer announced its Phase 3 Symbiotic-GI-03 trial (NCT07222800) evaluating PF-08634404, a novel bispecific antibody targeting both PD-1 and VEGF, combined with chemotherapy versus bevacizumab plus chemotherapy in first-line mCRC (non-BRAF-mutated, microsatellite-stable). Per ClinicalTrials.gov, the trial enrolls 800 patients across 156 sites, with primary completion expected March 2030. PF-08634404 combines immune checkpoint inhibition and anti-angiogenesis in a single molecule. Updated Phase 2 data will be presented at ASCO 2026 (May 29 – June 2).
Post angle: One molecule, two mechanisms. Pfizer bets big on PD-1×VEGF bispecific vs bevacizumab in 1L mCRC. 800 patients, 156 sites. If this works, it rewrites the frontline playbook. #CRC #ColorectalCancer #VEGF #ASCO2026
#4
Source: AACR 2026 / PR Newswire | Authors: Ultima Genomics | Published: April 17-22, 2026 (AACR 2026)
Score: 8/20 — Base AACR oral presentation (7) + biomarker-guided/precision (+1)
At AACR 2026, Ultima Genomics presented six abstracts (including oral and plenary sessions) on its ppmSeq whole-genome sequencing technology for MRD detection. A validation pilot of 50 plasma samples achieved ctDNA detection at low single-digit parts-per-million sensitivity using tumor-specific variants from prior WGS — without customized assay panels. A multicenter prospective Netherlands Cancer Institute study is monitoring ctDNA-based treatment response in ~500 CRC patients on systemic chemotherapy. This panel-free approach could democratize MRD monitoring for every colon cancer patient.
Post angle: MRD detection without custom panels? ppmSeq achieves parts-per-million ctDNA sensitivity using whole-genome sequencing. 500 CRC patients in prospective study. The future of surveillance just got more accessible. #MRD #ctDNA #CRC #AACR2026 #LiquidBiopsy
#5
Source: EClinicalMedicine (Lancet family) | Authors: Guiu B, Bailly C, Vibert E et al. | Published: April 17, 2026
Score: 7/20 — Base Other (5) + retrospective/real-world (+1) + biomarker-guided dosimetry (+1)
Based on PubMed data (DOI: 10.1016/j.eclinm.2026.103884), this prospective multicenter PROACTIF cohort from 34 French sites enrolled 989 HCC patients treated with Y90 glass microspheres (TheraSphere). Median OS was 21.8 months overall, 27.0 months for BCLC-B, and 48.6 months for patients who proceeded to curative surgery (10.7%). A strong dose-survival relationship was confirmed: mOS 16.8 months with tumor dose <200 Gy vs 30.7 months with ≥400 Gy (p<0.001). Serious treatment-related AEs occurred in only 3.7%. Results support dosimetry-guided Y90 across all BCLC stages.
Post angle: 989 HCC patients, one clear message: dose matters. Y90 with ≥400 Gy tumor dose = 30.7 months mOS. Personalized dosimetry is the key. And 10.7% converted to curative surgery. #HCC #LiverCancer #Y90 #SIRT #Dosimetry
Additional Papers of Interest
-
ESMO GI Oncology — Phase II: CD47 inhibitor magrolimab + bev-FOLFIRI did not improve PFS vs control (6.2 vs 6.7 mo), increased grade ≥3 AEs
-
Nature Health — 190-country analysis: 9.06M GI cancer cases by 2050 (+85%), CRC 11.6% of burden, biggest rises in PDAC diagnoses and CRC deaths
-
Hepatology Communications — PSM study: Y90 personalized dosimetry outperforms DEB-TACE in target response (88% vs 58% ORR) and retreatment rates in BCLC A-B HCC
-
Lancet Regional Health Europe — Itanet registry: Ki-67 prognostic as continuous variable, 15% cutoff identifies worse outcomes, 58.6% diagnosed incidentally
-
AACR 2026 — Whole-genome sequencing MRD test shows expanded clinical utility in colon cancer surveillance
-
GlobeNewswire — Novel targeted LNP bypasses liver accumulation, reaches colon tissue; CRC added alongside PDAC, ICC, and HCC as target indications
Back to all digests